Medtronic's MiniMed Exchange Offer Runs to October as Reimbursement Wins Reshape the Story

Medtronic faces a MiniMed spinoff deadline and a US reimbursement overhaul, while new CPT codes and cardiac clearances offer support.

Medtronic is asking investors to hold their nerve through a pair of overlapping transitions: the carve-out of its diabetes unit and a slow-moving overhaul of how its cardiovascular devices get paid for in the United States. The stock closed Friday at EUR 76.72, down 0.3% on the day and 3.6% over the past 30 days, putting the company's market value at roughly EUR 97.94 billion.

A Spinoff Clock and a Stock That Has Slipped

The centerpiece of the portfolio story is MiniMed, the diabetes business Medtronic intends to separate. The exchange offer tied to that split is set to expire on October 9, 2026, unless the company extends the deadline or wraps the transaction early. In mandatory filings with the U.S. Securities and Exchange Commission, Medtronic cautioned that its share price could come under pressure once the unit is no longer part of the group.

The market has already registered its unease. Since the separation was announced a little over three weeks ago, the shares have shed 2.2%. A separate disclosure — FDA clearance for the LigaSure RAS Maryland instrument on the Hugo robotic surgery platform roughly two weeks back — was followed by a 5.0% decline, underscoring how sensitive the equity has become to headlines on both sides of the portfolio.

Coding Wins Set Up 2028 Payments

While the spinoff machinery grinds on, Medtronic has secured a quieter but potentially more durable victory on the reimbursement front. The American Medical Association granted new Category I CPT codes for Altaviva, an implantable tibial neuromodulation system for urge incontinence, and for Symplicity Spyral, the renal denervation device used against hypertension. The new codes replace the previous Category III designations and take effect in January 2028, a shift expected to smooth coverage decisions by payers and simplify physician billing.

Cardiac Franchise Racks Up Clearances

Regulatory progress has come thick and fast in electrophysiology. Medtronic won both FDA approval and European CE marking for Affera Prism-2, its cardiac mapping software, and picked up CE certification for the PulseSelect ProxBox adapter together with its spacing-indicator software. Both tools are aimed at sharper control during cardiac procedures.

Further down the pipeline, the FDA handed Breakthrough Device designation to IN.PACT BTK, a drug-coated balloon catheter intended to treat vascular disease below the knee. The product remains in development, so no approval or market release is in place yet.

Analysts Keep the Faith

Against that operational backdrop, TD Cowen reaffirmed its Buy rating on Medtronic on September 30, 2026, keeping a price target of $110.00. The analysts pointed to the company's continued growth outlook as the rationale. For shareholders, the question now is how the completion of the MiniMed transaction will shape how the market values what remains of the core business.

Rounding out the picture, Medtronic was named to Fortune's 2026 "Change the World" list in recognition of its Touch Surgery ecosystem and Healthy Neighbor program.